PET and SPECT of cerebral neurotransmission;PET y SPECT de neurotransmisión cerebral

Revista Espanola de Medicina Nuclear

Volumn 22, Issue 2, 2003, Pages 109-121

  Catafau, A M ^a,c   Semih Dogan, A ^b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GSK Centre for Imaging in Psychiatry   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROTRANSMITTER; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

ALCOHOLISM; ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR ACCIDENT; DEPRESSION; EPILEPSY; GILLES DE LA TOURETTE SYNDROME; HUMAN; IMAGE ANALYSIS; NARCOLEPSY; NEUROTRANSMISSION; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BRAIN; BRAIN DISEASE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SCINTISCANNING; SYNAPSE; SYNAPTIC TRANSMISSION;

BRAIN; BRAIN DISEASES; HUMANS; SYNAPSES; SYNAPTIC TRANSMISSION; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0642286633     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1157/13044683     Document Type: Article

References (133)

1. 123I-IBZM. J Nucl Med 1992;33:1964-71.
2. 18F] cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 1993;13:24-42.
3. 123I] Epidepride SPECT in humans. J Nucl Med 2000;41:1343-51.
4. 123IBF SPECT. J Nucl Med 1996;37:513-20.
5. Verchoeff NPLG. Imaging neurotransmission and neuroreceptors- physiological and pharmacological basis. En: Costa DC, Morgan GF, Lassen NA eds. New trends in nuclear neurology and psychiatry. John Libbey & Company Ltd., 1993. p. 25-36.
6. 123I-IBZM using the rotating gamma camera. Nucl Med Com 1991;12:687-97.
7. 123I-FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 1997;27:183-90.
8. Links JM. Special issues in quantitation of brain receptors and related markers by emission computed tomography. Q J Nucl Med 1998;42:158-65.
9. Woods RP, Grafton ST, Watson JD, Sicotte NL Mazziotta JC. Automated image registration: intersubject validation of linear and nonlinear models. J Comput Assist Tomogr 1998;22(1):139-65.
10. 2 receptors. J Comp Assisted Tomography 1996;20(3):423-8.
11. th Annual Meeting, Toronto, Canada. 2001. p. 23-7.
12. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med 1998;39(5):904-11.
13. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984;15:217-27.
14. Ichise M, Meyer JH, Yonekura Y. An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med 2001;42:755-63.
15. Innis RB. Single photon emission computed tomography imaging of dopaminergic function: presynaptic transporter, postsynaptic receptor, and «intrasynaptic» transmiter. Adv Pharmacol 1998;42:215-9.
16. Kerwin RW, Pilowsky LS. Traditional receptor theory and its application to neuroreceptor measurements in functional imaging. Eur J Nucl Med 1995;22:699-710.
17. Kegeles LS, Mann JJ. In vivo imaging of neurotransmitter systems using radiolabeled receptor ligands. Neuropsychopharmacology. 1997;17:293-307.
18. 1 receptor binding in the monkey brain using PET. Psychopharmacology (Berl) 1991;103(2):150-3.
19. 2 dopamine receptor imaging agent. J Nucl Med 1989;30:88-92.
20. 2 receptors. Life Sci 1991;49:617-28.
21. 2 receptors. Life Sci 1991;49:617-28.
22. 2 dopamine receptors in the human using SPECT. In J Rad Appl Instrum B. 1992;19:523-9.
23. 11C-labelled raclopride, a new potent dopamine receptor antagonist: preliminary PET studies of cerebral dopamine receptors in the monkey. Int J Appl Radiat Isot 1985;36(4):269-73.
24. Wong DF, Gjedde A, Wagner HN Jr. Quantification of neuroreceptors in the living human brain. I. Irreversible binding of ligands. J Cereb Blood Flow Metab 1986;6(2):137-46.
25. 18F-N-methylsipiroperidol. Psychiatry Res 67:11-6.
26. Maziere B, Loch C, Hantraye P, et al. 76Br-bromospiroperidol: a new tool for quantitative in vivo imaging of neuroleptic receptors. Life Sci 1984;35(13):1349-56.
27. Neumeyer JL, Wang S, Gao Y, et al. N-omega-fluoroalkyl analogs of (1R)-2 beta-carbomethoxy-3 beta-(4-iodophenyl)-tropane (beta-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 1994;37:558-61.
28. 123I-FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 1997;27:183-90.
29. Kung MP, Essman WD, Frederick D, et al. IPT: a novel iodinated ligand for the CNS dopamine transporter. Synapse 1995;20:316-24.
30. Guilloteau D, Emond P, Baulieu JL, et al. Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4′-methylphenyl) nortropane (PE2I). Nucl Med Biol 1998;25:331-7.
31. 99mTc complex as a dopamine transporter imaging agent. Eur J Nucl Med 1997;24:372-80.
32. 127I]Altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse 2001;39(4):332-42.
33. 11C]WIN 35, 428. Synapse 1993;15(2):130-42.
34. 18F]fluoro-L-dopa for the in vivo study of intracerebral dopamine. Int J Rad Appl Instrum [A] 1986;37(8):669-75.
35. 123I-Iomazenil: kinetic and equilibrium paradigms. J Nucl Med 1994;35:228-38.
36. 123I labelled 3-(5-cyclopropyl-1,2,4-oxadioazo-3-yl)-7-yodo-5,6-dihidro-5-methyl-6-oxo-4H- imidazol[1,5a][1,4]-benzodiazepine (NNC-13-8241). Eur J Nucl Med 1996;16:273-80.
37. 18F]fluoroethyl)flumazenil to central benzodiazepine receptors measured in living baboon by positron emission tomography. Eur J Pharmacol 1992;218(1):109-15.
38. 11C-Ro 15-1788 and positron emission tomography. Kaku Igaku 1985;22(12):1789-97.
39. Mertens J, Terriere D, Sipido V, Gommeren W, Janssen PMF, Leysen JE. Radiosynthesis of a new radioiodinated ligand for serotonin-5HT2-receptors, a promising tracer for gamma-emission tomography. J Labelled Comp Radiopharm 1994;34:795-806.
40. 11C]MDL 100907, a radioligand for selective imaging of 5-HT(2A) receptors with positron emission tomography. Life Sci 1996;58(10):PL 187-92.
41. Houle S, DaSilva JN, Wilson AA. Imaging the 5-HT (1A) receptors with PET: WAY-100635 and analogues. Nucl Med Biol 2000;27(5):463-6.
42. Choi SR, Hou C, Oya S, Mu M, Kung MP, Siciliano M, et al. Selective in vitro and in vivo binding of [(125)I] ADAM to serotonin transporters in rat brain. Synapse. 2000;38: 403-12.
43. 11C](+)McN5652. Synapse 1995;20(1):37-43.
44. 123I-4-iododexetimide. J Cereb Blood Flow Metab 1992;12:562-70.
45. 123I-labelled E-IQNP. Eur J Nucl Med 2001;28:13-24.
46. 11C]tropanyl benzilate and positron emission tomography. J Nucl Med 1990;31:779 (Abstract).
47. 123I-MK-801: a SPECT agent for imaging the pattern and extent of glutamate (NMDA) receptor activation in Alzheimer's disease. J Psychiatr Res 1997;31:605-19.
48. 18F. Appl Radiat Isot 1988;39:1219-25.
49. Passchier J, Van Waarde A. Visualisation of serotonin-1A (5-HT1A) receptors in the central nervous system. Eur J Nucl Med 2001;28:113-129.
50. 123)I]iodo-3-(2-azetidinylmethoxy) pyridine of A-85380. Nucl Med Biol 2001;28:91-6.
51. 11C]A-84543: an enantioselective ligand for in vivo studies of neuronal nicotinic acetylcholine receptors. Life Sci 1998;63(1):PL13-8.
52. Bando K, Naganuma T, Taguchi K, et al. Piperazine analog of vesamicol: in vitro and in vivo characterization for vesicular acetylcholine transporter. Synapse 2000;38:27-37.
53. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996;40(3):399-410.
54. 11C dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter. J Cereb Blood Flow Metab 1997;17:919-31.
55. Wang RF, Tafani JA, Zajac JM, Guiraud R. A radioiodinated 7alpha-O-iodoallyl diprenorphine for mapping opioid receptors. Neuropeptides 1999;33:498-502.
56. Frost JJ, Wagner HN Jr, Dannals RF, Ravert HT, et al. Imaging opiate receptors in the human brain by positron tomography. J Comput Assisst Tomogr 1985;9(2):231-6.
57. 125I]iodobolpyramine. Neuroscience 1988;26:553-600.
58. 11C]doxepin and positron emission tomography. Neurosci Lett 1992;137(2):145-8.
59. 11C] pyrilamine and positron emission tomography. J Neurochem 1992;59(1):128-36.
60. Wong DF, Wagner HN, Dannals FR, et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984;226:1393-6.
61. 11C raclopride. J Cereb Blood Flow Metab 1993;13:310-4.
62. 2 and serotonin 5HT2 receptors in living human brain. Prog Neuropsychopharmacol Biol Psychiatr 1993;17:415-21.
63. Yanai K, Watanabe T, Meguro K, Yokoyama H, Sato I, Sasano H, et al. Age-dependent decrease in histamine H1 receptor in human brains revealed by PET. Neuroreport 1992;3(5):433-6.
64. Prevett MC, Lammertsma AA, Duncan JS, et al. Central benzodiazepine receptor quantitation (BZR) in normal and primary generalized epilepsy. J Cereb Blood Flow Metab 1993;13(Suppl. 1):S277.
65. Suhara T, Inoue O, Kobayashi K, Suzuki K, Tateno Y. Age-related changes in human muscarinic acetylcholine receptors measured by positron emission tomography. Neurosci Lett 1993;149:225-8.
66. Zelnik N, Ángel I, Paul SM, Kleinman JE. Decreased density of human striatal dopamine uptake sites with age. Eur J Pharmacol 1986;126:175-6.
67. De Keyser J, Ebinger G, Vauquelin G. Age-related changes in the human striatal dopamine uptake sites with age. Eur J Pharmacol 1986;126:175-6.
68. 2 receptor binding characteristics in vivo. Am J Psychiatry 1998;155:768-73.
69. Verhoeff NPLG. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders. Psychopharmacology 1999;147:217-49.
70. 2 densities and the schizophrenic brain. Schizophr Res 1998;32:201-6.
71. Tsuang TM, Faraone SV, Day M. Schizophrenic disorders, in Nicholi AM Jr (ed): The New Harvard Guide to Psychiatry. Cambridge, MA, Harvard University Press 1988. p. 259-95.
72. 11C]raclopride in the human brain. Synapse 1994;16:255-62.
73. Seeman P, Guan HC, Van T1 HHM. Dopamine D4 receptors are elevated in schizophrenia. Nature 1993;365:441-5.
74. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowes M, et al. Increased striatal dopamine transmision in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998;155:761-7.
75. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-3.
76. Dahl S. Plasma level monitoring of antipsychotic drugs: Clinical utility. Clin Pharmacokinet 1986;11:36-61.
77. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine in relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;481-3.
78. Wolkin A, Brodie JD, Barouche F, et al. Dopamine receptor occupancy and haloperidol levels. Arch Gen Psychiatry 1989;46:482-3.
79. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988;45:71-6.
80. 2 receptor blockade hypothesis of schizophrenia. Lancet 1992;340:199-202.
81. Wolkin A, Barouche F, Wolf AP, et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989;146:905-8.
82. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW. Limbic selectivity of clozapine. Lancet 1997;350:490-1.
83. 2 and 5-HT2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 1994;55:67-9.
84. 2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 1997;154:1525-9.
85. 2 and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995;152:1444-9.
86. Fowler JS, Volkow ND, Wolf AP, et al. Mapping of cocaine binding sites in human and baboon brain in vivo. Synapse 1989;4:371-7.
87. Dachis CA, Gold MS. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev 1985;9:469-77.
88. Volkow ND, Fowler JS, Wolf AP, et al. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 1990;147:719-24.
89. 11C-cocaine in human heart, lungs, liver and adrenals. A dynamic PET study. J Nucl Med 1992;33:521-5.
90. Volkow ND, Wang GJ, Fishman MW, Foltin RW, Fowler JS, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997;386:827-30.
91. 11C]WIN35,428 PET scans. Synapse 1999;32:44-50.
92. Fowler JS, Volkow ND, Wang GJ, et al. PET and drug research and development. J Nucl Med 1999;40:1154-63.
93. Volkow ND, Wang G-J, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylprenidate. Am J Psychiatry 1988;155:1325-31.
94. 18F]dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1990;28:547-55.
95. 18F]fluorodeoxyglucose and PET studies. Mov Disord 1990;5:203-13.
96. Wolters ECh, Huang C, Clark C, et al. Positron emission tomography in manganese intoxication. Ann Neurol 1989;26:647-51.
97. 18F]dopa PET study. Neurology 1993;43:552-6.
98. 18F]dopa positron emission tomography. Ann Neurol 30:24-30.
99. 11C]raclopride and positron emission tomography. Ann Neurol 1992;31:184-92.
100. 123I]IBZM single photon emission computed tomography. Arch Neurol 1993;50:513-6.
101. 123I]IBZM binding predicts dopamine responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. Mov Disord 1997;12:898-902.
102. 1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in monkey (Macaca fascicularis). Brain Res 1990;514:103-10.
103. Innis RB. SPECT imaging of dopamine terminal innervation: potential clinical tool in Parkinson's disease. Eur J Nucl Med 1994;21:1-5.
104. nd. Churchill Livingstone, New York, p. 521-62.
105. Kish SJ, Shannak K, Hornykiewics O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-80.
106. 123I]βCIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-7.
107. 123I iododexetimide cholinergic neuroreceptor single-photon emission computed tomography. Neurology 1996;47:1015-20.
108. 99mTc-HMPAO SPECT in patients with partial epilepsy. Ann Nucl Med 1998;12:185-90.
109. 123I iomazenil SPET: comparison with brain perfusion SPET and FDG PET. Eur J Nucl Med 1997;24:27-34.
110. Frost JJ, Mayberg HS, Fisher RS, et al. Mu-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy. Ann Neurol 1988;23(3):231-7.
111. 123I iodobenzamide single-photon emission tomography. Eur J Nucl Med 1997;24:609-14.
112. 123I-β-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997;24:320-5.
113. 99mTc-HMPAO-SPECT in Alzheimer's disease. J Nucl Med 1997;38:467-70.
114. 123I iomazenil SPECT in comparison with CBF. Ann Nucl Med 1999;13:309-15.
115. 123I dexetimide single-photon emission tomography. Eur J Nucl Med 1997;24:602-8.
116. Heinz A, Jones DW, Raedler T, Coppola R, Knable MB, Weinberger DR. Neuropharmacological studies with SPECT in neuropsychiatric disorders. Nucl Med Biol 2000;27: 677-82.
117. 2 receptors are differentially affected in AD: Neurology 2000;55(2):205-9.
118. Sasaki M, Ichiya Y, Kuwabara Y, Yoshida T, Fukumura T, Masuda K. Benzodiazepina receptors in chronic cerebrovascular disease: comparison with blood flow and metabolism. J Nucl Med 1997;38:1693-8.
119. 123I-iomazenil SPECT. J Nucl Med 1995;36:2154-61.
120. Nakagawara J, Sperling B, Lassen NA. Incomplete brain infarction of reperfused cortex may be quantitated with iomazenil. Stroke 1997;28:124-32.
121. Koshi Y, Kitamura S, Ohyama M, Komiyama T, Komaba Y, Sakayori O, et al. Benzodiazepine receptor imaging with iomazenil SPECT in aphasic patients with cerebral infarction. Ann Nucl Med 1999;13:223-9.
122. 11C]PK1195. Neurology 2000;55(7): 1052-4.
123. 123I]iomazenil. Am J Psychiatry 1998;155:1550-5.
124. 3 receptors in late onset type 1 alcoholic patients. Neurosci Lett 2000;292:57-9.
125. 2-receptor density in late-onset alcoholism. Psychopharmacology (Berl). 1999;147:314-8.
126. 123)I]iodobenzamide SPECT in the prediction of treatment outcome of alcohol-dependent patients. Am J Psychiatry 2000;157:127-9.
127. Gilman S, Koeppe RA, Adams K, et al. Positron emission tomographic studies of cerebral benzodiazepine-receptor binding in chronic alcoholics. Ann Neurol 1996;40(2):163-71.
128. 2-like dopamine receptor density in Tourette's syndrome measured by PET. J Nucl Med 1997;38:1243-7.
129. Ernst M, Zametkin AJ, Jons PH, et al. High presynaptic dopaminergic activity in children with Tourette's disorder. J Am Acad Child Adolesc Psychiatry 1999;38(1):86-94.
130. 123I]IBZM SPECT. Psychiatry Res 1999;90:91-101.
131. 2 receptors in striatum and anterior cingulate gyrus in major depression. Neuroimage 1997;5:251-60.
132. Staley JK, Malison RT, Innis RB. Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression. Biol Psychiatry. 1998;44:534-49.
133. Drevets WC, Frank E, Price JC, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 1999;46(10):1375-87.